Emmanuel Krakaris compensation by year
Augmedix Summary Compensation Table · all 3 fiscal years held| Component | FY2020 | FY2021 | FY2022 |
|---|---|---|---|
| Salary | $295,833 | $400,000 | $450,000 |
| Bonus | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $0 |
| Option awards | $127,440 | $1,072,139 | $423,150 |
| Non-equity incentive | $210,000 | $280,000 | $280,000 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $900 | $3,536 | $4,334 |
| Total | $634,173 | $1,755,675 | $1,157,484 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Augmedix, Inc. DEF 14A filed June 26, 2023, accession 0001213900-23-051693, and prior-year filings.
How this page was built: the Augmedix, Inc. filed document, accession 0001213900-23-051693. Every figure is read from that document and cited to the page and table it appears in. Filed June 26, 2023.
Equity holdings
unvested awards at FY2022 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 337,819 | — | $3.00 |
| Option | 363,961 | — | $3.00 |
| Option | 46,273 | — | $3.00 |
| Option | 264,062 | — | $2.48 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Augmedix, Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
16 Form 4 lines since the FY2022 proxy (filed June 26, 2023)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2024-10-02 | Disposition to the issuer | 10b5-1 | 64,748 | $2.35 | 0 |
| 2024-10-02 | Disposition to the issuer derivative | 10b5-1 | 800,820 | $0.00 | 0 |
| 2024-10-02 | Disposition to the issuer derivative | 10b5-1 | 831,637 | $0.00 | 0 |
| 2024-10-02 | Disposition to the issuer derivative | 10b5-1 | 131,250 | $0.00 | 0 |
| 2024-10-02 | Disposition to the issuer derivative | 10b5-1 | 100,000 | $0.00 | 0 |
| 2024-10-02 | Disposition to the issuer derivative | 10b5-1 | 325,000 | $0.00 | 0 |
| 2024-10-02 | Disposition to the issuer derivative | 10b5-1 | 363,961 | $0.00 | 0 |
| 2024-10-02 | Disposition to the issuer derivative | 10b5-1 | 505,036 | $0.00 | 0 |
The 8 most recent of 16 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Augmedix’s named executive officers, FY2022
as the company reported each| Named executive officer | Role | FY2022 total |
|---|---|---|
| Emmanuel Krakaris · this page | President, Chief Executive Officer and Secretary | $1,157,484 |
| Sandra Breber | Chief Operating Officer | $736,396 |
| Saurav Chatterjee | Chief Technology Officer | $633,352 |
Board service
Augmedix board · FY2022How this board is paid
Company policy: Augmedix pays directors a $40,000 cash retainer and $100,000 in equity. As stated in Augmedix's FY2022 proxy.
The full Augmedix compensation record
free company briefThis page is one person within Augmedix's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Augmedix's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.